Pyxis Oncology, Inc. (NASDAQ:PYXS) Stock Has Consensus Price Target of $8.75 According to Brokerages

Key Points

• Analyst sentiment is moderately positive: Ten brokerages give Pyxis Oncology a consensus “Moderate Buy” rating, with eight buys, one hold, and one sell. The average 12-month price target is $8.75.
• Institutional ownership remains significant: T3 Companies initiated a 26,100-share position worth about $61,000, while institutions collectively own 39.07% of the company.
• The stock remains speculative and unprofitable: PYXS opened at $1.98, versus a 12-month range of $1.03 to $5.55, and recently reported an adjusted loss of $0.40 per share, missing estimates of $0.35.

Shares of Pyxis Oncology, Inc. (NASDAQ:PYXS - Get Free Report) have been given an average recommendation of "Moderate Buy" by the ten ratings firms that are covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and eight have given a buy rating to the company. The average 12-month target price among brokers that have issued ratings on the stock in the last year is $8.75.

A number of equities research analysts have weighed in on the company. Wedbush boosted their price objective on Pyxis Oncology from $6.00 to $8.00 and gave the company an "outperform" rating in a research note on Thursday, September 10th. Leerink Partners decreased their price objective on Pyxis Oncology from $9.00 to $7.00 and set an "outperform" rating for the company in a report on Thursday, July 2nd. Weiss Ratings restated a "sell (e+)" rating on shares of Pyxis Oncology in a research report on Friday, September 25th. Wells Fargo & Company lifted their target price on shares of Pyxis Oncology from $12.00 to $19.00 and gave the company an "overweight" rating in a report on Wednesday, September 9th. Finally, HC Wainwright upped their price target on shares of Pyxis Oncology from $7.00 to $8.00 and gave the company a "buy" rating in a research report on Thursday, September 10th.

Institutional Inflows and Outflows

An institutional investor recently bought a new stake in Pyxis Oncology stock. T3 Companies LLC acquired a new stake in Pyxis Oncology, Inc. (NASDAQ:PYXS - Free Report) during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 26,100 shares of the company's stock, valued at approximately $61,000. Hedge funds and other institutional investors own 39.07% of the company's stock.

Pyxis Oncology Price Performance

Shares of NASDAQ:PYXS opened at $1.98 on Thursday. Pyxis Oncology has a 12 month low of $1.03 and a 12 month high of $5.55. The firm has a market capitalization of $165.15 million, a P/E ratio of -1.40 and a beta of 1.37. The company's fifty day moving average price is $2.71 and its 200 day moving average price is $2.16.

Pyxis Oncology (NASDAQ:PYXS - Get Free Report) last released its quarterly earnings data on Thursday, August 13th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($0.05). On average, sell-side analysts anticipate that Pyxis Oncology will post -1.21 EPS for the current year.

Pyxis Oncology Company Profile

Pyxis Oncology, Inc is a clinical-stage biotechnology company focused on developing antibody-based therapies for the treatment of cancer. The company aims to address limitations of existing cancer treatments by designing therapeutics intended to selectively target tumors and activate the immune system while minimizing effects on healthy tissue.

Pyxis Oncology's pipeline includes antibody-drug conjugates and immunotherapies designed to act on targets in the tumor microenvironment. Its lead programs have included PYX-201, an antibody-drug conjugate intended to deliver a cytotoxic payload to tumors expressing the fibronectin extra domain-B target, and other investigational antibody-based programs directed at immune-suppressive pathways.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.